Wednesday, May 24, 2017 8:13:03 AM
Recent GLYC News
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/25/2024 11:00:00 AM
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 • Business Wire • 03/27/2024 11:00:00 AM
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 • Business Wire • 03/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:16:05 PM
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 12:00:00 PM
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 02/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:12 PM
- GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 • Business Wire • 01/04/2024 12:00:00 PM
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:05:19 PM
- GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia • Business Wire • 12/10/2023 05:00:00 PM
- GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference • Business Wire • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:35:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 12:31:36 PM
- GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 • Business Wire • 11/03/2023 11:00:00 AM
- Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board • PR Newswire (US) • 10/23/2023 12:30:00 PM
- GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 • Business Wire • 10/20/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:15:43 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM